An Open-label, Study to Assess Safety, Efficacy and Cellular Kinetics of YTB323 in Severe, Refractory Systemic Lupus Erythematosus

Phase 1/2 Active not recruiting 21 enrolled Novartis Pharmaceuticals

NaSingle-groupOpen-labelTreatment

Summary

The study is intended to assess safety, efficacy and cellular kinetics of YTB323 treatment in participants with severe refractory systemic lupus erythematosus.

Timeline

Start: 2023-02-28
Primary completion: 2026-09-24
Completion: 2026-09-24

Drugs

Evaluation	Drug	Modality	Dose	Route
Subject	rapcabtagene autoleucel	Cell therapy	—	—

An Open-label, Study to Assess Safety, Efficacy and Cellular Kinetics of YTB323 in Severe, Refractory Systemic Lupus Erythematosus

Summary

Timeline

Drugs

Indications